Press release
Advanced Gastric Carcinoma Clinical Trials Analysis 2025: Targeted Agents, Immuno-Oncology Therapies, and Novel Combinations Aim to Improve Survival and Response Rates | DelveInsight
Advanced Gastric Carcinoma Clinical Trials Analysis
The AGC pipeline is progressing with targeted therapies including HER2-directed agents, CLDN18.2-targeted antibodies, and FGFR2 inhibitors, which offer biomarker-driven treatment approaches. Immuno-oncology interventions, such as PD-1/PD-L1 inhibitors and dual checkpoint blockade strategies, are being investigated both as monotherapies and in combination with chemotherapy or targeted agents to improve anti-tumor efficacy. ADCs and bispecific antibodies are emerging as promising modalities to deliver cytotoxic therapy while minimizing systemic toxicity selectively.
Development strategies also focus on combination regimens, maintenance therapies, and personalization based on molecular profiling, including HER2, PD-L1, and microsatellite instability status. Clinical trials increasingly incorporate patient-reported outcomes to capture functional and quality-of-life improvements alongside conventional efficacy endpoints, reflecting a patient-centered approach to care.
With multiple late-stage candidates progressing globally, the advanced gastric carcinoma treatment landscape is poised to shift toward precision oncology, combining biomarker-guided targeted therapy with immuno-oncology interventions to extend survival, improve response rates, and optimize overall patient outcomes in this challenging malignancy.
Curious about the latest breakthroughs in advanced gastric carcinoma treatment? Discover cutting-edge drugs and the evolving pipeline-click here to explore: https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report
• DelveInsight's advanced gastric carcinoma pipeline analysis depicts a strong space with 50+ active players working to develop 50+ pipeline drugs for advanced gastric carcinoma treatment.
• The leading advanced gastric carcinoma companies include Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others are evaluating their lead assets to improve the advanced gastric carcinoma treatment landscape.
• Key advanced gastric carcinoma pipeline therapies in various stages of development include Camrelizumab, Pamiparib, Mitoxantrone Hydrochloride Liposome, Catumaxomab, Ipilimumab, Relatlimab, FLX475, DP303c, IDX-1197, HLX22, Olaparib, LCAR-C18S, ALX148, KN026, Atezolizumab, Sintilimab, QL1604, NC410, KH903, GQ1001, Amivantamab, IMU-131, BT8009, VE800, CPL304110, ARX788, MRG002, SEA-TGT, and others.
• In July 2025, Adcentrx Therapeutics announced that the FDA granted orphan drug designation to ADRX-0405, a STEAP1-targeting antibody-drug conjugate (ADC), for the treatment of gastric cancer. ADRX-0405 is currently in Phase 1a/b trials for advanced solid tumors, including gastric cancer, metastatic castration-resistant prostate cancer, and non-small cell lung cancer.
• In March 2025, the FDA granted traditional approval for frontline KEYTRUDA in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma with PD-L1 CPS ≥1. Additionally, the FDA granted orphan drug designation to the anti-HER2 monoclonal antibody HLX22 for the treatment of patients with gastric cancer.
• In February 2025, Signet Therapeutics announced that the FDA granted fast track designation to SIGX1094 for treating diffuse gastric cancer.
• In January 2025, the FDA approved tislelizumab-jsgr (tislelizumab) for the first-line treatment of unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adult patients with PD-L1-expressing tumors.
• In December 2024, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), announced the FDA approval of TEVIMBRA® (tislelizumab-jsgr) in combination with platinum and fluoropyrimidine-based chemotherapy for first-line treatment of unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults with PD-L1 expression (≥1).
• In October 2024, Astellas Pharma Inc. announced the FDA approval of VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma with CLDN18.2 positivity, determined by an FDA-approved test. VYLOY is the first CLDN18.2-targeted therapy approved in the U.S.
Request a sample and discover the recent breakthroughs happening in the advanced gastric carcinoma pipeline landscape @ https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Gastric Carcinoma Overview
Advanced stomach cancer occurs when cancer originating in the stomach spreads to other parts of the body, such as the liver, lungs, lymph nodes, or the peritoneum. The symptoms vary depending on the affected organs, but common signs include unexplained weight loss, nausea, stomach pain, difficulty swallowing, and fatigue.
At an advanced stage, treatment focuses on symptom management and disease control. External radiotherapy can help alleviate discomfort, while chemotherapy, targeted therapy, and radiotherapy may reduce symptoms. Additional interventions, such as laser therapy or stents, can address blockages in the stomach. In some cases, surgery is used to relieve obstructions. Laser therapy, which uses high-intensity beams to destroy cancer cells, is another option for symptom management in advanced stomach cancer.
Find out more about advanced gastric carcinoma @ https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Gastric Carcinoma Treatment Analysis: Drug Profile
Camrelizumab: JiangsuHengrui Medicine
Camrelizumab (HR 301210, INCSHR 1210, SHR 1210) is a humanized IgG4-kappa monoclonal antibody designed to target the programmed cell death-1 (PD-1) receptor. It is currently undergoing Phase III clinical trials for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Pamiparib: BeiGene
Pamiparib (BGB-290) is an experimental small molecule inhibitor of PARP1 and PARP2. It is being studied as a monotherapy in pivotal clinical trials in China for recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. Globally, it is under development both as a monotherapy and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), to treat various solid tumors.
Learn more about the novel and emerging advanced gastric carcinoma pipeline therapies @ https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Gastric Carcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Advanced Gastric Carcinoma Pipeline Report
• Coverage: Global
• Key Advanced Gastric Carcinoma Companies: Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
• Key Advanced Gastric Carcinoma Pipeline Therapies: Camrelizumab, Pamiparib, Mitoxantrone Hydrochloride Liposome, Catumaxomab, Ipilimumab, Relatlimab, FLX475, DP303c, IDX-1197, HLX22, Olaparib, LCAR-C18S, ALX148, KN026, Atezolizumab, Sintilimab, QL1604, NC410, KH903, GQ1001, Amivantamab, IMU-131, BT8009, VE800, CPL304110, ARX788, MRG002, SEA-TGT, and others.
Dive deep into rich insights for drugs used for advanced gastric carcinoma treatment; visit @ https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Advanced Gastric Carcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Advanced Gastric Carcinoma Pipeline Therapeutics
6. Advanced Gastric Carcinoma Pipeline: Late-Stage Products (Phase III)
7. Advanced Gastric Carcinoma Pipeline: Mid-Stage Products (Phase II)
8. Advanced Gastric Carcinoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Gastric Carcinoma Clinical Trials Analysis 2025: Targeted Agents, Immuno-Oncology Therapies, and Novel Combinations Aim to Improve Survival and Response Rates | DelveInsight here
News-ID: 4196343 • Views: …
More Releases from DelveInsight
Advanced Urothelial Carcinoma Clinical Trials Analysis 2025: Targeted Therapies, …
DelveInsight's "Advanced Urothelial Carcinoma (aUC) - Clinical Trials Analysis, 2025" examines a dynamic pipeline focused on improving survival, response rates, and tolerability for patients with locally advanced or metastatic disease. Despite the availability of platinum-based chemotherapy and checkpoint inhibitors, a significant portion of patients experience disease progression or relapse, highlighting a critical unmet need for innovative treatments.
The aUC clinical landscape is rapidly evolving, with next-generation targeted therapies, such as FGFR…
Post-Polycythemia Vera Myelofibrosis Clinical Trials Analysis 2025: Novel JAK In …
DelveInsight's "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Clinical Trials Analysis, 2025" highlights an evolving pipeline designed to tackle the limitations of current therapies and improve long-term outcomes for patients with this rare secondary myeloproliferative neoplasm. While JAK inhibitors such as ruxolitinib and fedratinib remain the cornerstone of treatment, their benefits are primarily palliative, with limited disease-modifying activity. This gap has spurred innovation toward agents capable of reducing fibrosis, improving survival rates,…
Immunologic Deficiency Syndrome Clinical Trials Analysis 2025: Gene Therapies, N …
DelveInsight's "Immunologic Deficiency Syndrome - Clinical Trials Analysis, 2025" reviews the rapidly evolving clinical landscape for primary and selected secondary immunodeficiency disorders, a heterogeneous group of conditions characterized by impaired host defense and recurrent, sometimes life-threatening infections. While lifelong immunoglobulin replacement and hematopoietic stem cell transplant (HSCT) remain cornerstones for many patients, persistent unmet needs - including incomplete immune reconstitution, treatment burden, infection risk, and long-term complications - are driving…
Vestibular Schwannoma Clinical Trials Analysis 2025: Hearing-Preservation Strate …
DelveInsight's "Vestibular Schwannoma - Clinical Trials Analysis, 2025" examines the evolving clinical-trial landscape for vestibular schwannoma (VS). This typically benign cranial nerve tumor can cause hearing loss, tinnitus, and balance dysfunction. While microsurgery and stereotactic radiosurgery remain primary treatment options, unmet needs, particularly in durable hearing preservation, facial nerve function protection, and treatments for NF2-associated progressive disease, are driving focused clinical development.
The VS clinical pipeline features several complementary approaches: refinement…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
